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Abstract
Background: Medication can be effective but can also be harmful and even cause hospital admissions. Medication
review or pharmacotherapy review has often been proposed as a solution to prevent these admissions and to
improve the effectiveness and safety of pharmacotherapy. However, most published randomised controlled trials
on pharmacotherapy reviews showed no or little effect on morbidity and mortality. Therefore we designed the
PHARM (Preventing Hospital Admissions by Reviewing Medication)-study with the objective to study the effect of
the total pharmaceutical care process on medication related hospital admissions and on adverse drug events,
survival and quality of life.
Methods/Design: The PHARM-study is designed as a cluster randomised, controlled, multi-centre study in an
integrated primary care setting. Patients with a high risk of a medication related hospital admission are included in
the study with randomisation at GP (general practitioner) level. We aim to include 14200 patients, 7100 in each
arm, from at least 142 pharmacy practices.
The intervention consists of a patient-centred, structured, pharmaceutical care process. This process consists of
several steps, is continuous and occurrs over multiple encounters of patients and clinicians. The steps of this
pharmaceutical care process are a pharmaceutical anamnesis, a review of the patient’s pharmacotherapy, the
formulation and execution of a pharmaceutical care plan combined with the monitoring and follow up evaluation
of the care plan and pharmacotherapy. The patient’s own pharmacist and GP carry out the intervention. The
control group receives usual care.
The primary outcome of the study is the frequency of hospital admissions related to medication within the study
period of 12 months of each patient. The secondary outcomes are survival, quality of life, adverse drug events and
severe adverse drug events. The outcomes will be analysed by using mixed-effects Cox models.
Discussion: The PHARM-study is one of the largest controlled trials to study the effectiveness of the total
pharmaceutical care process. The study should therefore provide evidence as to whether such a pharmaceutical
care process should be implemented in the primary care setting.
Trial Registration: Trial number: NTR 2647
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Background
Drug regulatory authorities give a medicine marketing
authorisation if the balance between efficacy and safety is
considered positive, based on the available evidence in the
studied population. On the level of the individual patient
treated with one or more drugs in daily clinical practice, it
is, however, hard to predict whether the positive effects
outweigh the negative effects. Individual (patho)physiolo-
gical and psychological characteristics of the patient, con-
comitantly used medication as well as the treatment
setting, can largely modulate pharmacokinetics, pharmaco-
dynamics and behaviour of the patient and thereby treat-
ment outcomes. Unfortunately for some patients the net
effect of pharmacotherapy is not positive but harmful. For
example, several studies have shown that 3-5% of all
hospital admissions is medication related [1].
The Dutch multi-centre HARM-study on medication-
related hospital admissions, showed that almost half
(46%) of these admissions were considered as potentially
preventable admissions. Patients who were especially at
risk of medication-related admissions were elderly
patients with multiple drug use, who are cognitively
impaired or who are non-adherent to their pharma-
cotherapy [1-5].
Medication review or pharmacotherapy review has
often been proposed as a solution to improve the effec-
tiveness and safety of pharmacotherapy [2]. However,
most published randomised controlled trials on pharma-
cotherapy reviews showed no or little effect on morbid-
ity and mortality [6,7]. These studies differed largely
with respect to the nature and extensiveness of the
review techniques, the outcomes studied, setting and
follow-up time and results are therefore difficult to com-
pare. One study reported an increase in emergency
readmissions [8], while in the other studies there is no
suggestion that patients were harmed by the interven-
tions [9,10], and even some consistency in suggesting
that falls [11] and hospital admissions [12,13] might be
reduced. Potentially relevant elements in these studies
were a review of a fully available medical and drug his-
tory, structured pharmaceutical care plan approach,
combined effort of pharmacist and GP and involvement
and commitment of the patient.
Hence there is still a need for large studies to evaluate
the effectiveness of a so called patient centred pharmaceu-
tical care process, including reviewing pharmacotherapy,
formulating a pharmaceutical care plan and monitoring
and follow up evaluating of pharmacotherapy, in daily
practice of an integrated primary care setting. Therefore
we designed the PHARM-study with the objective to study
the effect of the total pharmaceutical care process on med-
ication related hospital admissions and on adverse drug
events, survival and quality of life in patients with a high
risk of medication related hospital admissions. This study
is a practice based, cluster randomised controlled inter-
vention study in an integrated primary care setting in the
Netherlands. The study design with its explanation and
definition of the different steps in of the pharmaceutical
care process will be described in this paper. The results of
the study will be presented in a separate paper.
Methods/Design
Participants
Only patients at high risk for a medication-related hos-
pital admission are included in the study. To identify
these patients we used risk factors from the HARM
study as inclusion criteria [2]. This resulted in four cri-
teria regarding age, polypharmacy, type of drug class
used and non-adherence [14]. (See table 1 for detailed
information on inclusion criteria) Patients could be
included if they met all four of these criteria
The number of included patients is limited to the
capacity of the GP and the pharmacist. If too many
patients are eligible for inclusion, random selection by
computer based on patient serial number, is used within
the eligible group of one GP and pharmacist, to comply
with the limit. The pharmacist and GP both can include
patients in 2008 and 2009, with a follow-up period of
12 months.
Patients are excluded if they are resident in a nursing
home, if their life expectancy is less than three months
or if they will not give informed consent. Patients have
to be withdrawn from the study when they are no
longer a patient of the participating GP or pharmacist.
This is possible when a patient moves to another area
or to a nursing home or when a patient withdraws his/
her informed consent.
The study is conducted in agreement with the princi-
ples of the Declaration of Helsinki (Edinburgh 2000)
and was approved by the medical ethical review board
of METOPP (Medisch-Ethische Toetsing Onderzoek
Patiënten en Proefpersonen). The patient’s pharmacist
explains the procedure, possible benefit and burden of
participation in the study to each patient and provides
an informed consent form approved by METOPP. The
patient is asked to sign the form prior to inclusion into
the study. Patient data from this study are coded by the
patient’s own pharmacist. Analysing and publication of
the results of this study will be performed anonymously.
Study setting
The study is carried out from 2008 to 2010 in an inte-
grated primary care setting, by the patient’s own GP,
pharmacist and practice nurse if available. All Dutch
GPs, practice nurses and pharmacists working in pri-
mary care will be informed about the study and invited
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to participate by mail, by websites, by several articles in
pharmacy and GP journals and by several presentations
at regional meetings or at national symposia. They are
asked to cooperate as a group of at least one pharmacist
and at least two GPs. This cooperation includes sharing
data from electronic medical records required for the
study. The GPs are allocated as an intervention GP or a
control GP, by random selection.
Support
Before and during the intervention period the GP and
the pharmacist are offered support by training, educa-
tion and a web based community of practice with a
helpdesk on pharmacotherapy. The web-based commu-
nity of practice offers a place of sharing information and
experiences within the group of participants, provides
all materials for the study and establishes for the
researchers a place to encourage and support the parti-
cipants and monitor the progress of the study. The
pharmacist receives training on communication skills
focussing on the pharmaceutical anamnesis, motivation
of patients and communicating with the GP. The GP
and the pharmacist participate together in at least three
workshops on the study protocol, assessment of phar-
macotherapy and the assessment of adverse drug events.
The helpdesk is managed by a clinical pharmacist with
support of experts on pharmacotherapy, medication
safety and care of the elderly.
The GP from the control patients does not received
any additional training or support, other than generally
in usual care.
Intervention
The intervention consists of a patient-centred, struc-
tured, pharmaceutical care process. This process con-
sists of several steps, is continuous and occurs over
multiple encounters of patients and clinicians. The steps
of this pharmaceutical care process are a pharmaceutical
anamnesis, a review of the patient’s pharmacotherapy,
the formulation and execution of a pharmaceutical
care plan to combine with the monitoring and follow up
evaluation of the care plan and pharmacotherapy (see
figure 1).
Pharmaceutical anamnesis
The purpose of the pharmaceutical anamnesis is to
gather information from the patient and its drug ther-
apy. The anamnesis is performed by the pharmacist who
meets the patient at home or in a private consultation
room at the pharmacy or at the GP practice. During the
pharmaceutical anamnesis the patient’s medication use
and experiences therewith are discussed, including the
patient’s current pharmacotherapy, drug history, drug
use, possible allergies or intolerabilities and concomitant
use of OTC drugs or other health products, but also the
patient’s beliefs, perceptions, understandings, attitudes,
and concerns of the pharmacotherapy.
Pharmacotherapy review
The purpose of the pharmacotherapy review is to iden-
tify potential drug therapy related problems, and phar-
maceutical care issues. A pharmaceutical care issue is
defined as an element of a patient’s drug related need,
which can lead to a drug therapy related problem. We
define a drug therapy related problem as any undesir-
able event or risk thereof, experienced by the patient
that involves or is suspected to involve pharmacotherapy
and that actually or potentially interferes with the
desired patient outcome [15,16]. The pharmacist identi-
fies these possible drug therapy related problems (DTPs)
by combining sociological, pathophysiological and phar-
macological knowledge of the patient in a systematic
way. This structure is derived from the classification by
Strand et al. as defined and described in table 2 and in
table 3. The pharmaceutical care issues are described in
table 4.
Pharmaceutical care plan
The purpose of the pharmaceutical care plan is to
organize all of the pharmaceutical care agreed upon by
the pharmacist, the GP, the practice nurse and the
Table 1 Definition of the inclusion criteria of the PHARM-study
Criterion Definition
65 years or older 65 Years of age or older, at the time of inclusion.
polypharmacy Five or more drugs with different chemical substances. Every separate drug is prescribed and dispensed, at least 3 times in the
12 months before inclusion and dispensed at least once in the 6 months before inclusion.
ATC A or ATC B
drug
One or more drugs from the Anatomical Therapeutic Chemical (ATC)[25]
class A; “alimentary tract and metabolism” or ATC class B; “blood and blood forming organs”. At least one of each drug
prescribed and dispensed in the 12 months before inclusion.
non-adherence At least one drug with a refill rate below 0.8 or above 1.2 This refill rate was calculated by dividing the number of dispensed
daily doses, by the number of days between the first and the last prescription dispensed. The refill rate was calculated for all
chronically prescribed drugs, as defined above under polypharmacy, of which at least 60 daily doses were dispensed in the 12
months before inclusion. The number of dispensed daily doses was calculated by summing the dispensed daily doses between
the first to the last prescription date and multiplying it by factor 1.1 to correct for irregular drug use and early collection of the
prescription. The refill rate was only calculated for oral and inhalation drugs with a clearly prescribed dose regimen. It was
therefore not calculated for PRN (Pro Re Nata = as needed) drugs.
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patient to achieve the goals of pharmacotherapy by
addressing, resolving and preventing drug therapy pro-
blems. Together they formulate a care plan and the
pharmacist specifically is responsible for the monitor-
ing and the follow-up evaluation of the care plan and
pharmacotherapy.
After establishing the drug therapy problems they are
categorized based on a medical condition and on the
drug therapy. When multiple drug therapy problems are
present, they are prioritized based on the patient’s per-
spective, focussing on those that causes the most con-
cern and which one the patient is willing to address.
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Figure 1 Design of the PHARM-study.
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The next step is to set the goals of the drug therapy
and to agree on the interventions to achieve these
goals. The interventions include start, stop or switch
drug therapy, adjusting the dosage regimens or formu-
lation, monitoring of drug therapy, referral to other
clinician and individualized patient counselling and
education. All these interventions are documented in
the pharmaceutical care plan with detailed information
on who is responsible for a certain action (GP,
pharmacist or practice nurse), when the action will be
taken and when it will be evaluated.
Monitoring and follow-up evaluation of care plan and
pharmacotherapy
The focus of the monitoring and follow-up evaluation of
pharmacotherapy is on the implementation of the phar-
maceutical care plan. The pharmacist, the GP and if
needed the patient, verify if all planned interventions are
completed and they examine the outcomes of the
Table 2 Classification and definition of drug therapy problems
Category of
drug therapy
problem
Question to identify drug therapy problem Drug
therapy
problem
Definition
Indication Does the patient have an indication for each of his/her
drug therapies, and is each of the patient’s indications
being treated with drug therapy?
Additional
drug therapy
required
The patient has a medical condition or is experiencing
symptoms that requires the initiation of new or additional
drug therapy or is at a high-risk to develop a new
medical condition for which additional drug therapy is
indicated.
Unnecessary
drug therapy
The patient is taking drug therapy that is unnecessary
given his or her present condition or the patient is at risk
to develop a new medical condition that is a result of
taking an unnecessary drug for which there is no valid
medical indication.
Effectiveness Are the drug therapies effective for his/her medical
condition? Are the intended outcomes of drug therapy
reached?
Ineffective
drug therapy
The drug product is not being effective at producing the
desired response. The patient is not experiencing the
intended positive outcome from a certain drug regimen
or the intended outcome is not reached. Or an alternative
drug therapy has a higher probability of producing the
desired outcome, or an alternative drug therapy is equally
effective but less expensive.
Dosage too
low
The patient has a medical condition for which too little of
the correct drug is being taken to produce the desired
beneficial outcome or the patient is at risk to develop a
new medical condition because too little of the correct
drug is being taken to expect a beneficial outcome. The
patient’s drug concentration in the body can be below
the desired therapeutic range or the timing of prophylaxis
can be inadequate for the patient or dose and interval
can be inadequate for the patient or drug, dose, route or
formulation conversions were inadequate for the patient.
Safety Are the drug therapies as safe as possible? Is everything
done to keep them as safe as possible?
Adverse
drug event
The patient has a medical condition or is experiencing
symptoms or is at risk of developing a medical condition
which is undesired effect and is related to the drug
therapy. This can be an idiosyncratic reaction to the drug,
an allergic reaction to the drug or a pharmacologically
expected reaction to the drug, possible due to a
medication error.
Dosage too
high
The patient has a medical condition for which too much
of the correct drug is being taken or the patient is at risk
to develop a new medical condition because too much
of the correct drug is being taken. The patient’s drug
concentration in the body can be above the desired
therapeutic range or the drug dose escalating can be too
rapidly or there can be drug accumulation from chronic
administration or dose and interval can be inadequate for
the patient or drug, dose, route or formulation
conversions were inadequate for the patient.
Drug use Is the patient able and willing to comply with the drug
therapies as prescribed? Are the drug therapies as
convenient as possible to the patient?
Drug use
problem
Drug use problem is defined as the patient’s inability or
unwillingness to take a drug regimen that the GP,
pharmacist or other health care provider has clinically
judged to be appropriately indicated, adequately
efficacious and able to produce the intended outcomes
without any undesired effects.
Leendertse et al. BMC Health Services Research 2011, 11:4
http://www.biomedcentral.com/1472-6963/11/4
Page 5 of 13
Table 3 Description of drug therapy problems
Drug therapy
problem
Common causes of drug therapy problem Examples
Additional drug
therapy
required
• A medical condition requires the initiation of drug therapy.
• Preventive drug therapy is required to reduce the risk of
developing a new condition (according to the national
guidelines).
• A medical condition requires additional pharmacotherapy to
produce an additive of synergistic effect.
• The patient is suffering from pain with no analgesic
therapy.
• A patient with chronic heart failure due to left ventricular
systolic dysfunction, without an ACE-inhibitor or an
angiotensin receptor blocker.
• A patient with atrial fibrillation without antithrombotic
therapy.
• Calcium and vitamin D supplements for a patient with
osteoporosis who is already taking a bisphosphonate.
Unnecessary
drug therapy
• There is no current valid medical indication for the drug
therapy for the individual patient.
• Multiple drug products are being used for a medical
condition that requires single drug therapy.
• The medical condition is more appropriately treated with
non-drug therapy or lifestyle changes.
• Drug therapy is being taken to treat an avoidable adverse
event associated with another medication.
• Lifestile ( e.g. drug abuse, alcohol use, diet, smoking) is
causing the problem.
• A patient is using a low dose of aspirin without a high
risk of cardiovascular disease or any signs of a
cardiovascular disease.
• A patient is using three different laxative products in an
attempt to treat his constipation.
• A patient is using a benzodiazepine every night as a
hypnotic drug for three years while it is better to
recommend alternative sleeping patterns, sleep hygiene
and exercise.
• A patient is using furosemide to prevent swollen ankles.
• A patient is using paracetamol combined with codeine
(500/10) and is suffering from constipation which is
treated with lactulose and bisacodyl occasionally.
• A patient uses a protonpump inhibitor to treat dyspepsia
associated with alcohol abuse.
Ineffective drug
therapy
• The drug is not effective for the medical problem.
• The drug product is not the most effective for the
indication being treated.
• The formulation of the drug products is inappropriate.
• The drug is not effective because of the characteristics of
the patient. (e.g. renal impairment, hepatic function)
• A patient is using an antibiotic for a common cold (viral
infection).
• A patient with benign prostatic hyperplasia uses
doxasozine for more than four years.
• • A patient with severe COPD uses salbutamol in a
turbuhaler.
• A patient with renal impairment uses a thiazide to lower
the blood pressure.
Dosage too
low
• The dose is too low to produce the desired outcome.
• The dosage interval is too long to produce the desired
outcome.
• A drug-drug interaction reduces the amount of active drug
available and the dose is not adjusted too produce the
desired outcome.
• The duration of the drug therapy is too short to produce
the desired outcome.
• A patient is prescribed simvastatine 10 mg every other
day after a myocardial infarction.
• A patient uses 500 mg paracetamol, only twice a day, to
control chronic pain in osteoarthritis.
• A patient uses 375 mg amoxicilline, only once a day, to
treat an airway infection.
• A patient uses acenocoumarole and vitamin K.
• A patient uses paroxetine for 4 days to treat anxiety.
Adverse drug
event
• The drug causes an undesirable reaction that is not dose-
related.
• A safer product is required due to risk factors.
• A drug interaction, with another drug or food, causes an
undesirable reaction that is not dose-related.
• The drug is contraindicated due to risk factors or other
diseases.
• The drug causes an allergic reaction.
• A drug dosage was increased or decreased too fast.
• A drug alters the patient’s laboratory test results due to
interference from a drug he/she uses.
• A patient on a low dose of aspirin is experiencing
bruises.
• An elderly patient uses flurazepam to sleep and is
experiencing drowsiness at day time.
• A patient who uses methotrexate gets prescribed co-
trimoxazole for an infection (increase of anti-folate effect
which can result in haematopoietic suppression).
• A patient gets prescribed indometacin to control chronic
pain, which is contraindicated because of his/her history
with a peptic ulcer.
• A patient is prescribed flucloxacillin for a dermal
infection and develops a rash after the second dose.
• A patient who uses prednisolone 20 mg every day for
the last 6 months for arthritis symptoms iss instructed to
take 10 mg for 2 more days and then discontinues the
medication.
• A patient had high blood glucose levels, due to the start
of prednisolone therapy.
• Positive ketone test in urine due to captopril use.
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documented drug therapy problems. They also assess if
the goals of drug therapy are achieved. At this evalua-
tion moment it is possible to plan new interventions to
achieve previously documented goals of therapy or to
solve previously identified drug therapy problems. The
pharmacist documents the outcomes and possible new
interventions in the care plan.
Control group
Patients in the control group receive usual care from
their GP, pharmacist, practice nurse and other primary
health care staff. This care consists of repeat prescrip-
tions and medication surveillance according to the cur-
rent clinical guidelines.
Outcomes
The primary outcome of the study is the frequency of
hospital admissions related to medication within the
study period of 12 months of each patient. Two inde-
pendent clinical pharmacists assess all admissions for a
causal relationship between the reason for admission
and the medication use, prior to the admission. This is
done by reviewing the, blinded, discharge letter com-
bined with the medical and medication data from an
electronic Case Report Form (CRF), according to the
adjusted Kramer algorithm [17].
The secondary outcomes are survival, quality of life,
adverse drug events and severe adverse drug events. The
quality of life is measured by the EuroQol EQ5D com-
bined with the VAS (visual analogue scale) questionnaire
at the start of the inclusion period and at the end of the
inclusion period, after 12 months [18]. The pharmacist
and the GP ask the patient at the end of the study per-
iod about symptoms of the past 3 months. They report
and assess the adverse drug events according to the
adjusted Kramer algorithm [17] combined with National
Coordinating Council for Medication Error Reporting
and Prevention (NCC MERP) scheme for categorisation
of the severity of the events [19].
Table 4 Classification and definition of pharmaceutical care issues
Pharmaceutical care
issue
Definition
Monitoring An intermittent (regular or irregular) series of observations in time, carried out to determine the effectiveness, safety and
adherence of the drug therapy.
Drug-drug interaction A combination of two or more drugs, administered by one patient that can result in a modification of the effect of at least
one drug. The effect may be an undesired effect or a lack of effect of the drug.
Contra-indicated drug A drug that is undesired because of the medical condition of the patient, which can lead to an adverse drug event or a
lack of effect of the drug or a worsening of the medical condition of the patient.
Lifestyle The lifestyle of the patient that could interfere with effective and safe drug therapy or that could result in non-adherence.
Double medication Therapeutic duplication is defined as the use of two or more drugs in the same ATC classification and with similar
pharmacodynamic properties, which can lead to adverse drug events.
Table 3 Description of drug therapy problems (Continued)
Dosage too
high
• The drug causes an undesirable reaction due to too high
dose.
• The dosing frequency of the drug is too short.
• The duration of drug therapy is too long.
• The drug dose is too high in the patient because of its
characteristics (excretion).
• A drug-drug interaction occurs resulting in a toxic reaction
to the drug.
• The dose of the drug was administered too rapidly.
• A patient develops bradycardia resulting from a high (0.5
mg) daily dose of digoxine.
• Hyperkaleamia after a dose of amiloride 10 mg three
times a day.
• A patient who experienes nasal congestion uses a nasal
spray with xylometazoline for four weeks.
• A patient with impaired renal function (CrCl: 20 ml/min)
is prescribed a normal dose of 300 mg allopurinole a day,
which causes nausea.
• A patient has an increased INR after given metronidazole
while also using acenocoumarole.
• Cardiac arrest after infusion of a bolus of potassium
phosphate (5 ml intravenously) instead of slow infusion.
Drug use
problem
• • The patient does not understand the instructions.
• The patient prefers not to take the medication.
• • The patient forgets to take the medication.
• • The patient cannot administer the drug appropriately him/
herself.
• • The drug therapy does not comply with the lifestyle of the
patient.
• • The patient has no access to the medication.
• The patient uses naproxen only when pain is unbearable
while it is prescribed three times a day.
• The patient is afraid of taking fluvoxamine because of
possible side-effects.
• The patient forgets to take his antihypertensive
medication.
• The patient is unable to administer the timolol eyedrops
for her glaucoma.
• A patient does not take furosemide because of
attending activities at home.
• A patient is not able to fetch the medication at the
pharmacy.
Leendertse et al. BMC Health Services Research 2011, 11:4
http://www.biomedcentral.com/1472-6963/11/4
Page 7 of 13
Other outcomes are the frequency and type of drug
therapy problems (table 2) as documented in the phar-
maceutical care plans over the intervention period. Two
independent pharmacists code from the care plans, all
the drug therapy problems, the proposed and executed
intervention combined with the drug therapy. They
meet to reach consensus when needed.
Sample size
We expect to achieve an effect of 50% reduction of
medication-related hospital admissions [2,20]. It seems
possible to include 50 intervention patients from one
intervention GP and 50 control patients from one con-
trol GP in one pharmacy practice, in a period of
12 months with a follow-up period of 12 months. To
show a statistically significant difference between the
intervention and the control arm with an expected pre-
valence of 0.01 (1%), we plan to include 14200 patients,
7100 in each arm, from at least 142 pharmacy practices
and at least 284 GP practices to participate in the
PHARM-study [21,22]. This is based on an alpha of 0.05
and a power (1-beta) of 0.8. It should be noted that the
prevalence of HARM is expected to be higher in the
group eligible for inclusion in the study.
Distribution of inclusion criteria
To determine the size of the population at risk and
therefore eligible for inclusion, we searched the ‘Kring-
kubus-database’ [23]. This database contains anonymous
drug dispensing data from 100 (5.5%) community phar-
macies, spread throughout the Netherlands, belonging
to the franchise organization ‘Kring-apotheek’ (n = 330).
In the Dutch community pharmacies, the drug history
of individual patients can be considered as nearly com-
plete because most patients visit only one single phar-
macy [24]. This database includes drug-dispensing data
from 719,022 patients with patient related information
(age, sex, unique anonymous identifier), information on
the dispensed drug (chemical substance coded according
to the Anatomical Therapeutic Chemical (ATC) system
[25] and dispensed product), date of dispensing, amount
dispensed and prescribed dosage regimen. Patients who
complied with the defined risk factors and therefore
with the inclusion criteria as well (table 1), were selected
from the database by using Microsoft Access. The use of
the drug-dispensing data was performed in compliance
with the Dutch privacy regulations.
We found that in an average pharmacy practice 6.4%
(range: 1.5 - 15.0%) of the patients had a high risk of
being admitted to hospital with a medication-related
cause, according to the HARM-risk model. In an aver-
age Dutch pharmacy practice the size of this high-risk
population was around 450 patients, enough eligible
patients for participating in the PHARM-study. The
type of drug (ATC class A; alimentary tract and
metabolism or ATC class B; blood and blood forming
organs) risk factor was the most common risk factor in
the population of a pharmacy: 37.2% (range: 23.8 -
48.8%), while non-adherence was the smallest risk factor
in the population of a pharmacy: 22.4% (range: 15.6 -
37.7%). The relative numbers of high risk patients per
risk factor in the Dutch pharmacies and the distribution
of these risk factors are presented in the box plots in
figure 2. The numbers of high-risk patients per risk fac-
tor and the overlap between the risk factors are pre-
sented in the Venn diagram in figure 3.
Randomisation
Cluster randomisation takes place after informed con-
sent of the participating GPs and pharmacists on a GP
level and before the selection of patients. For every
pharmacist a random selection of the intervention GP is
made. The other participating GP becomes the GP who
will include control patients.
Data analysis
From each included patient data are collected in an
electronic CRF containing: patient data, medical history
and complaints, clinical data, quality of life and visual
analogue scale, drug history with drug-allergies and
drug-intolerabilities and a part with information on hos-
pital admissions and adverse drug events. Detailed infor-
mation on the data collected in the CRF can be found
in table 5. The pharmacist and the GP complete the
CRF with data from the pharmacy database, the GP
database and from the interview with the patient. The
collected data are based on literature and present guide-
lines [26-28].
Figure 2 Proportion of the patients at HARM risk in a
pharmacy with the distribution of the risk factors in the
pharmacies in the ‘Kring-kubus’ database.
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For the intervention patients the CRF also contains a
separate part for documenting the pharmacotherapy
review, the pharmaceutical care plan and monitoring
and follow up evaluation of pharmacotherapy. In this
plan information is organised according to drug therapy
related problems with the Subjective-Objective-Assess-
ment-Plan (SOAP) notes method [29]. The assessment
and evaluation of the different drug therapy problems
are subsequently documented and prioritised and the
subsequent interventions are documented with specific
information on who of the clinicians is taking the
action, when the action is taken and when the action is
evaluated.
Data from the digital Excel CRF and from a Microsoft
Access database are combined and further analysed by
using R, version 2.6.2. In R mixed-effects Cox models [22]
are designed to study the effect of the intervention on hos-
pital admissions related to medication and the effect on
survival, quality of life and adverse drug events. All avail-
able patient data are included. The pharmacist and the GP
are integrated as random effects in the models. P-values <
0.05 are regarded as statistically significant. The two-sided
Figure 3 The number of high-risk patients per risk factor and the overlap between the risk factors (total patient population: 719,022).
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Table 5 Data collection; content of case report form (CRF)
Part Data content
Patient data • patient ID*
• age*§
• gender*§
• pharmacist*§
• GP*§
• weight#/+
• lengths#/+
• diet+
• alcohol consumption+
• smoking habits+
• cognition$
• abilities/disabilities+
• daily activities+
• former education\language+
• religion+
• home situation+
• home help+
• carer+
• medication aids+
• other relevant information (free text) +
Medical data • acute medical conditions (menu, coded with ICPC-code[31])#
• chronic medical conditions (menu, coded with ICPC-code[31])* #
• current complaints or symptoms (menu, coded with ICPC-code[31]) #
• significant past medical conditions or procedures#
• other relevant health information (free text) #
Clinical data • laboratory values#
• blood pressure#
• temperature#
• weight#
• other relevant measured clinical data#
available clinical data is collected from 12 months before inclusion till the end of the inclusion period.#
Medication data full drug history: all dispensed drugs from 12 months before inclusion till the end of the inclusion period§, containing
information on:
• chemical substance (menu, coded with ATC-code[25]) §
• dispensed product (extracted from pharmacy database)* §
• dispensed amount (extracted from pharmacy database)* §
• dispensing date (extracted from pharmacy database)* §
• prescribed dose (extracted from pharmacy database)* §
• over the counter (OTC) drugs§, +
• vitamins, dietary or nutritional supplements§, +
• other health products§, +
• medical devices§, +
• drug allergies§, +
• intolerabilities or adverse drug events§, +
Study outcomes • hospital admissions (discharge letter as appendix)#
• date of each admissions#
• reason for eacht admission#
• quality of life; EQ5D score (at t = 0* and t = 12 months)+
• visual analogue scale score(at t = 0* and t = 12 months) +
• adverse drug events (ADE) with symptom, related drug and timing information (at t = 12 months) +, #
• severity of the ADE+, #
Pharmaceutical care
plan$
• DTPs (according to the Subjective-Objective-Assessment-Plan (SOAP) notes[29])
• therapy goals
• priorities
• interventions
• clinician who is executing the action
• date of action
• date of evaluation of the action
* obligatory; $ for intervention patients only
# Obtained from medical record
§ Obtained from medication record
+ Obtained from the patient during pharmaceutical anamnesis or questionnaire
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95% bootstrap percentile confidence intervals are com-
puted using 1000 replications. Bootstrap samples are
obtained by random sampling GP’s or patients with repla-
cement from the population. To assess the model’s good-
ness of fit we create plots of outcome versus follow-up
time, versus number of diseases and examined residuals.
The influence of the baseline characteristics such as age,
gender, number of physicians, number of diseases, number
of drug prescribed, refill rate and follow-up time are also
analysed using linear mixed-effects models or generalized
linear mixed-effects models.
Discussion
The PHARM-study looks into the effect of the complex
pharmaceutical care process on medication related hospi-
tal admissions. This patient centred pharmaceutical care
process is highly patient individualized, includes several
steps (figure 1) and is conducted in a primary care set-
ting. This care process can only be partly structured in a
study protocol because it is dependent on patients ’
autonomy, the performance of the clinicians and on the
cooperation between them. These issues cannot be com-
pletely restrained to a protocol and will be a reflection of
real clinical practice. In the PHARM-study the effective-
ness of the pharmaceutical care process will be studied in
daily clinical practice and due to this the study is a prag-
matic trial. Such a trial is suitable to evaluate effective-
ness rather than to measure efficacy [30].
A key methodological issue in pragmatic trials is bal-
ancing internal and external validity [30]. This issue is
addressed for the PHARM-study in the study design
and evaluation protocol. External validity, or generaliz-
ability, is achieved by allowing the GPs and the pharma-
cists to implement the intervention in their own manner
within their daily practice. External validity is also
addressed by having very few exclusion criteria and gen-
eral inclusion criteria. The included high-risk patients
are a heterogeneous group, with multiple and varying
morbidities and medication usage. Internal validity is
maintained by selecting intervention patients from
another general practitioner than the control patients, to
reduce contamination bias by ensuring that GPs do not
apply strategies and knowledge used in the intervention
patients to control patients.
We expect this study to have several other strengths
besides internal and external validity. First, we have
gained experience during several previous pilot projects
and because of this we were able to optimize the inter-
vention by providing a structure for the pharmacotherapy
review. We have also optimized the CRF for documenta-
tion of the pharmaceutical care and the planned inter-
vention in drug therapy to guarantee the continuity of
care. Since pharmacotherapy and medical services
become more complex, creating a comprehensive
documentation is required to facilitate collaboration
between members of the health care team and ensure
continuity of care. Second, the pharmacist and the GP
are offered a training regarding the study protocol, the
documentation and how to perform a structured phar-
macotherapy review. A third strength is the large group
of patients, which makes it possible to measure a possible
effect on medication related hospitalisations. A fourth
strength is the extensive intervention during a period of
12 months in an interdisciplinary setting in cooperation
between the patient and the own GP and pharmacist,
which makes it more likely to solve all major drug ther-
apy problems.
This study also has some limitations. First, selection
bias may occur by just including patients who are will-
ing to cooperate in the intervention. However, the same
selection will take place in the control group because
they also have to cooperate in completing the question-
naires. Second the selection of the participating pharma-
cist and GPs is based on voluntary participation. Only
motivated couples of GPs and a pharmacist who estab-
lished a good cooperation will participate in the study,
which hampers the generalizability. But in case the
intervention shows an effect, these participating GPs
and pharmacists can be a role model for their colleagues
in the region. A third limitation is the extensive and
therefore demanding intervention. It is thinkable that it
will not be implemented as described in the protocol
because this is not possible or feasible in daily practice.
A fourth limitation is the selection of intervention and
control patients on a general practice level but from the
same pharmacy which implies that control patients are
cared for by the same pharmacist as the intervention
patient. This possibly leads to contamination bias, but
we do not expect that the pharmacist will provide other
care than usual care to the control patients. A fifth lim-
itation is the assessment of the ADEs which will be
done by the patient’s own pharmacist and GP who are
not blinded to the assignment to intervention or control
group. Knowing to which group the patient is assigned,
may possibly affect their judgement of ADEs, which can
potentially lead to the detection of more ADEs in the
control group. On the other hand an advantage may be
that they know their patients so they can make a better
judgement if the symptoms are related to the medica-
tion or to a disease.
The PHARM-study is one of the largest controlled
trials to study the effect of the total pharmaceutical care
process, including a pharmaceutical anamnesis, followed
by a pharmacotherapy review, a pharmaceutical care
plan, monitoring and follow up evaluation of pharma-
cotherapy, in an ordinary integrated primary care setting
on medication related hospital admissions. Few con-
trolled trials in this area have been performed and none
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have investigated the extensive intervention of the total
pharmaceutical care process, performed in cooperation
of the patient, the pharmacist, the GP and the practice
nurse, in this group of high risk patients, at the scale of
this study either in terms of the number of practices or
the number of patients. The PHARM-study should pro-
vide evidence as to whether such a pharmaceutical care
process should be implemented in a primary care setting
in the Netherlands.
Acknowledgements
The authors would like to thank Svetlana V. Belitser, MSc for providing
statistical support, Marjolein M.M. Geleedst-de Vooght, PharmD, Matthijs M.
Engering, PharmD and Frank A. van Wees, PharmD for participating in the
pilot study of the PHARM-study.
The PHARM-study is part of a larger study program, entitled
“Implementation of interventions for preventing adverse drug events in high
risk populations in primary care and care institutions, by a team of doctors
and hospital pharmacists”. This study program was financially supported by
a non-conditional grant of the Patient Safety Program of the Netherlands
Organisation for Health Research and Development (ZonMw) (file number
8140.0001). ZonMw has no role in the study design, collection, analysis and
interpretation of data, in writing the manuscript and in the decision to
submit the manuscript for publication.
Author details
1SIR Institute for Pharmacy Practice and Policy, Theda Mansholtstraat 5b
2331 JE, Leiden, the Netherlands. 2Utrecht Institute for Pharmaceutical
Sciences (UIPS), Division of Pharmacoepidemiology & Clinical Pharmacology,
Faculty of Science, Utrecht University, PO Box 80 082, 3508 TB, Utrecht, the
Netherlands. 3Patient Safety Center, University Medical Center Utrecht, PO
Box 85.500, 3508 GA, Utrecht, the Netherlands. 4Kring Pharmacies, PO Box
210, 5201 AE, ‘s-Hertogenbosch, the Netherlands. 5Dutch College of General
Practioners (NHG), PO Box 3231, 3502 GE Utrecht, the Netherlands. 6Jonkhoff
huisartsenpraktijk, Joh. de Breukstraat 42, 2021 HB, Haarlem, the Netherlands.
7Department of Pharmacotherapy and Pharmaceutical Care, University of
Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands.
8Department of Clinical Pharmacy, University Medical Center Utrecht, PO Box
85.500, 3508 GA, Utrecht, the Netherlands. 9Department of Hospital
Pharmacy, Erasmus Medical Center, PO Box 2040 3000 CA, Rotterdam, the
Netherlands.
Authors’ contributions
All authors are responsible for interpretation of the data and are involved
with drafting and critically reviewing the manuscript. AL, FK, AG, AJ, AG, TE
and PB are responsible for study design and study implementation. AL and
SB (see acknowledgements) are responsible for analysis of the population at
risk. All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 1 July 2010 Accepted: 7 January 2011
Published: 7 January 2011
References
1. Leendertse AJ, Visser D, Egberts ACG, van den Bemt PMLA: The
relationship between study characteristics and the prevalence of
medication-related hospitalizations: a literature review and novel
analysis. Drug Saf 2010, 33:233-44.
2. Leendertse AJ, Egberts ACG, Stoker LJ, van den Bemt PMLA, HARM Study
Group: Frequency of and risk factors for preventable medication-related
hospital admissions in the Netherlands. Arch Intern Med 2008, 168:1890-6.
3. Aparasu RR, Fliginger SE: Inappropriate medication prescribing for the
elderly by office-based physicians. Ann Pharmacother 1997, 31:823-829.
4. Walker J, Wynne H: Review: the frequency and severity of adverse drug
reactions in elderly people. Age Ageing 1994, 23:255-9.
5. Horne R, Weinman J, Barber N, et al: Concordance, adherence and
compliance in medicine taking: report for the National Co-ordinating
Centre for NHS Service Delivery and Organisation R&D. London:
NCCSDO; 2005.
6. Holland R, Desborough J, Goodyer L, Hall S, Wright D, Loke YK: Does
pharmacist-led medication review help to reduce hospital admissions
and deaths in older people? A systematic review and meta-analysis. Br J
Clin Pharmacol 2008, 65:303-16.
7. Zermansky AG, Silcock J: Is medication review by primary-care
pharmacists for older people cost effective?: a narrative review of the
literature, focusing on costs and benefits. Pharmacoeconomics 2009,
27:11-24.
8. Holland R, Lenaghan E, Harvey I, Smith R, Shepstone L, Lipp A, Christou M,
Evans D, Hand C: Does home based medication review keep older
people out of hospital? The HOMER randomised controlled trial. BMJ
2005, 330:293-7.
9. Richmond S, Morton V, Cross B, Chi Kei Wong I, Russell I, Philips Z, Miles J,
Hilton A, Hill G, Farrin A, Coulton S, Chrystyn H, Campion P, RESPECT trial
team: Effectiveness of shared pharmaceutical care for older patients:
RESPECT trial findings. Br J Gen Pract 2010, 59:14-20.
10. Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D, Duffus PR,
Downie G, Seymour DG: Pharmacist-led medication review in patients
over 65: a randomized, controlled trial in primary care. Age Ageing
2001, 30:205-11.
11. Zermansky AG, Alldred DP, Petty DR, Raynor DK, Freemantle N, Eastaugh J,
Bowie P: Clinical medication review by a pharmacist of elderly people
living in care homes: randomised controlled trial. Age Ageing 2006,
35:586-91.
12. Schnipper JL, Kirwin JL, Cotugno MC, Wahlstrom SA, Brown BA, Tarvin E,
Kachalia A, Horng M, Roy CL, McKean SC, Bates DW: Role of pharmacist
counseling in preventing adverse drug events after hospitalization. Arch
Intern Med 2006, 166:565-71.
13. Stewart S, Pearson S, Luke CG, Horowitz JD: Effects of home-based
intervention on unplanned readmissions and out-of-hospital deaths.
J Am Geriatr Soc 1998, 46:174-80.
14. Steiner JF, Prochazka AV: The assessment of refill compliance using
pharmacy records: methods, validity, and applications. J Clin Epidemiol
1997, 50:105-16.
15. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD: Drug-related
problems: their structure and function. DICP 1990, 24:1093-7.
16. Cipolle RJ, Strand LM, Morley PC: Pharmaceutical care practice: the
clinician’s guide. New York: McGraw-Hill;, 2 2004.
17. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR: An algorithm for
the operational assessment of adverse drug reactions, I: background,
description, and instructions for use. JAMA 1979, 242:623-31.
18. The EuroQol Group: EuroQol-a new facility for the measurement of
health-related quality of life. Health Policy 1990, 16:199-208.
19. National Coordinating Council for Medication Error Reporting and
Prevention (NCC_MERP): NCC MERP Index for categorizing medication
errors. 2010 [http://www.nccmerp.org/].
20. Stichting Farmaceutische Kengetallen: Polyfarmacie. Pharm Weekbl 2005,
32:968.
21. Campbell MK, Thomson S, Ramsay CR, MacLennan GS, Grimshaw JM:
Sample size calculator for cluster randomized trials. Comput Biol Med
2004, 34:113-25.
22. Brown H, Prescott R: Multi-Centre Trials and Meta-Analyses. Applied Mixed
Models in Medicine. 2 edition. West Sussex: JohnWiley & Sons Ltd; 2006.
23. Geerts AF, De Koning FH, De Smet PA, Van Solinge WW, Egberts TC:
Laboratory tests in the clinical risk management of potential drug-drug
interactions: a cross-sectional study using drug-dispensing data from
100 Dutch community pharmacies. Drug Saf 2009, 32:1189-97.
24. Buurma H, Bouvy ML, De Smet PA, Floor-Schreudering A, Leufkens HG,
Egberts AC: Prevalence and determinants of pharmacy shopping
behaviour. J Clin Pharm Ther 2008, 33:17-23.
25. WHO Collaborating Centre for Drug Statistics Methodology: Complete ATC
index. 2009 [http://www.whocc.no/atcddd/].
26. Floor-Schreudering , De Smet AP, Buurma H, Egberts CA, Bouvy LM:
Documentation Quality in Community Pharmacy: Completeness of
Electronic Patient Records After Patients’ First Visits. Ann. Pharmacother
2009, 43:1787-94.
Leendertse et al. BMC Health Services Research 2011, 11:4
http://www.biomedcentral.com/1472-6963/11/4
Page 12 of 13
27. (KNMP) Royal Dutch Association for the Advancement of Pharmacy: Dutch
Pharmacy Standard (NAN). The Hague, Netherlands; 2006.
28. Koda-Kimble MA, Young LL, Kradjan WA, Guglielmo BJ: Applied
therapeutics. The clinical use of drugs. Philadelphia: Lippincott Williams &
Wilkins;, 9 2008.
29. Weed LL: The problem oriented record as a basic tool in medical
education, patient care and clinical research. Ann Clin Res 1971, 3:131-4.
30. Godwin M, Ruhland L, Casson I, MacDonald S, Delva D, Birtwhistle R,
Lam M, Seguin R: Pragmatic controlled clinical trials in primary care: the
struggle between external and internal validity. BMC Med Res Methodol
2003, 3:28.
31. Lamberts H, Wood M: International Classification of Primary Care. Oxford:
Oxford University Press; 1988.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6963/11/4/prepub
doi:10.1186/1472-6963-11-4
Cite this article as: Leendertse et al.: Preventing hospital admissions by
reviewing medication (PHARM) in primary care: design of the cluster
randomised, controlled, multi-centre PHARM-study. BMC Health Services
Research 2011 11:4.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Leendertse et al. BMC Health Services Research 2011, 11:4
http://www.biomedcentral.com/1472-6963/11/4
Page 13 of 13
